stockrow
Friday 6 November 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024.
- Revenue
- +1.73%
- EPS
- +40.7%
- Free cash flow
- −41.3%
- Total debt
- +2.45%
Quarter to June 2026, against a year earlier
3.26
0.27
−7.65%
Follow TLSI
Alert me
TriSalus Life Sciences, Inc. (TLSI) P/E ratio
TriSalus Life Sciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 33.4× (November 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
Low 0.0×
High 33.4×
Ten-year median
0.0×
Current reading's percentile
80
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RXST RxSight, Inc. compare | n/m |
| INGN Inogen, Inc compare | n/m |
| STIM Neuronetics, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| PROF Profound Medical compare | n/m |
| TLSI TriSalus Life Sciences, Inc. | n/m |
| LAB Standard BioTools Inc. compare | 1.8× |
| ELMD Electromed, Inc. compare | 19.7× |
| INFU InfuSystems Holdings, Inc. compare | 32.7× |
| Medical Devices industry median | 24.9× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)